Press release
Less than six weeks to go until SMi’s RNA Therapeutics Conference
SMi announce key highlights ahead of RNA Therapeutics 2020, including topics to be discussed and confirmed attendees.In less than 6 weeks, the doors will open to SMi's RNA Therapeutics Conference, returning to London in February for its 11th year.
The event will feature an unparalleled, international line-up of industry-leading senior experts sharing their pioneering research, experience, and perspectives on RNA Therapeutics. Delegates will explore the recent advancements made in the ever-evolving field including mRNA therapeutic approach to pulmonary disease; microRNA-based drugs; small activating RNAs as a novel therapeutic class of oligonucleotides and self-amplifying mRNA vaccines, and more.
Highlights for RNA Therapeutics 2020:
• There will be a focus day to discuss the innovations in oligonucleotide delivery systems
• Delegates will explore the latest developments in RNA delivery agents and RNA-based therapeutics
• Delegates will learn from case studies on clinical developments with leading RNA therapeutics companies and regulatory bodies
• The event will revisit the challenges for clinical translation of RNA-based therapeutics
• Presentations will evaluate the applications of RNA-based drugs for modulation of gene and protein expression, and genome editing
• Attendees will gain an expert view on new and upcoming regulatory updates and industry implications
Delegates will benefit from exclusive networking time with speakers and attendees alike, all dedicated to furthering research in the ever-evolving field of RNA therapeutics. Participants who have already confirmed their place at the conference include BioNTech RNA Pharmaceuticals, GSK, AstraZeneca, JSC R-PHARM, Roche Diagnostics Deutschland, Nanogenics Ltd, MiNA Therapeutics, Medicines & Healthcare products Regulatory Agency (MHRA), BianoGMP, Ethris, NHS Blood and Transplant Authority, Nitto Avecia, InteRNA Technologies, Imperial College London, eTheRNA, Pantherna Therapeutics and more.
On top of this, there will be a pre-conference focus day on 18th May titled Oligonucleotide Delivery Systems, which will present sessions that showcase a myriad of delivery approaches such as optimising nanoparticle delivery to treat cancer and fibrosis; a review of common NA-LNP tolerability concerns to improve safety of nucleic acid therapeutics and the utility of light-triggered liposomes for retinal delivery.
For more information visit www.therapeutics-rna.com/openpr7
RNA Therapeutics
Focus Day: 18th February 2020
Conference: 19th – 20th February 2020
Copthorne Tara Hotel, London, UK
Proudly sponsored by:
--- ENDS –
Contact Information:
For sponsorship enquiries contact Alia Malick on +44 (0)20 7827 6168
For all delegate enquiries, contact Hakam Panum on +44 (0)20 7827 6128
SMi Group
Ground Floor, India House, 45 Curlew Street
London, SE1 2ND
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Less than six weeks to go until SMi’s RNA Therapeutics Conference here
News-ID: 1890837 • Views: …
More Releases from SMi Group
![Darren Green, GSK, conference chair invitation to attend 3rd Annual AI in Drug Discovery Conference](https://cdn.open-pr.com/V/1/V123110131_g.jpg)
Darren Green, GSK, conference chair invitation to attend 3rd Annual AI in Drug D …
SMi Reports: Conference Chairman Darren Green from GSK personally invites you the 3rd Annual AI in Drug Discovery Conference taking place on 14th and 15th March 2022 in London, UK.
The conference will have a focus on case studies from leading pharma and biotech firms, as well as a exploring the latest innovations in machine learning for enhancing discovery pipelines.
Darren Green, Director of Computational Chemistry at GSK will be chairing at…
![Registration is open for SMi’s 5th Annual Pharmaceutical Microbiology East Coast 2022](https://cdn.open-pr.com/V/1/V109775274_g.jpg)
Registration is open for SMi’s 5th Annual Pharmaceutical Microbiology East Coa …
SMi Group reports: The 5th Annual Pharmaceutical Microbiology East Coast Conference is set to return in April 2022 with a key focus existing methods and novel tools in microbial control to assure continuity in product quality and patient safety.
SMi Group is delighted to announce the 5th Annual Pharmaceutical Microbiology East Coast Conference, taking place on the 27th and 28th April 2022 in Boston, USA.
The 2022 Conference theme is…
![SMi’s 10th Annual Pharmaceutical Microbiology UK Conference - A Virtual Conference with Online Access Only](https://cdn.open-pr.com/U/c/Uc20486873_g.jpg)
SMi’s 10th Annual Pharmaceutical Microbiology UK Conference - A Virtual Confer …
SMi Reports: SMi Group have made the decision to open the microbiology conference and workshops to all microbiologists by transforming it into a virtual-remote online access event only on 17th and 18th January 2022.
SMi’s 10th Annual Pharmaceutical Microbiology UK Conference will no longer take place in London, UK. Instead, the conference is taking place on 17 and 18 January 2022 and will open its doors to a global audience delivering…
![Co-chairs Philip Hewitt and Stefan Pryzyborski, invitation to join SMi’s 5th Annual 3D Cell Culture Conference](https://cdn.open-pr.com/U/c/Uc07205035_g.jpg)
Co-chairs Philip Hewitt and Stefan Pryzyborski, invitation to join SMi’s 5th A …
SMi Group reports: Co-Chairs, Philip Hewitt and Stefan Pryzyborski for SMi’s 5th Annual 3D Cell Culture invite industry professionals to join the conference in February 2022.
Philip Hewitt, Global Head of Early Investigative Toxicology, Merck and Stefan Przyborski, Professor in Cell Technology, Durham University invite industry professionals by releasing invite letter to join SMi’s 5th Annual 3D Cell Culture Conference 2022.
This event will convene on February 9th – 10th 2022,…
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand.
Browse 156 Market Data Tables and 112 Figures spread through 175…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited.
Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring…
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year.
Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved…
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018!
Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led…
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion.
One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and…